



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/723,955	11/26/2003	Ruoping Chen	AREN-007CON2(7.US29.CON)	3273

65643 7590 02/28/2008
BOZICEVIC, FIELD & FRANCIS LLP
(ARENA PHARMACEUTICALS, INC.)
1900 UNIVERSITY AVENUE
SUITE 200
EAST PALO ALTO, CA 94303

EXAMINER

BASI, NIRMAL SINGH

ART UNIT	PAPER NUMBER
----------	--------------

1646

MAIL DATE	DELIVERY MODE
-----------	---------------

02/28/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

10723955

11/26/03

CHEN ET AL.

AREN-

007CON2(7.US29.CON)

BOZICEVIC, FIELD & FRANCIS LLP
(ARENA PHARMACEUTICALS, INC.)
1900 UNIVERSITY AVENUE
SUITE 200
EAST PALO ALTO, CA 94303

EXAMINER

NIRMAL S.. BASI

ART UNIT	PAPER
----------	-------

1646

20080218

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The amendment filed on 11/5/07 canceling all claims drawn to the elected invention and presenting only claims drawn to a non-elected invention is non-responsive (MPEP § 821.03). The newly added claims 69-87 are not readable on the elected invention because the elected invention is drawn to method of using a G protein-coupled receptor of SEQ ID NO:82 to screen candidate compounds as pharmaceutical agents for a disease or disorder ameliorated by an elevation of an intracellular level of cAMP in peripheral blood leukocytes (see, Office action dated 10/10/06, and Applicants response dated 2/2/07). Newly added claims 69-87 are drawn to a method of screening for a compound that increases cAMP levels in peripheral blood leukocytes comprising contacting a compound with a G protein coupled receptor that is 80% identical to the amino acid sequence of SEQ ID NO:82. The newly added invention does not screen for candidate compounds as pharmaceutical agents for a disease or disorder ameliorated by an elevation of an intracellular level of cAMP in peripheral blood leukocytes.

Since the above-mentioned amendment appears to be a bona fide attempt to reply, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIRMAL S. BASI whose telephone number is (571)272-0868. The examiner can normally be reached on 9:00 AM-5:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gary B. Nickol/
Supervisory Patent Examiner, Art Unit 1646

/Nirmal S. Basi/
Examiner, Art Unit 1646